JNJ buys Glaxo hep C treatment

Johnson & Johnson's (JNJ -0.7%) purchase of GlaxoSmithKline's (GSK -1%) hepatitis C treatment sends Idenix Pharmaceuticals (IDIX -15.8%) tumbling. JNJ bought the rights to a compound in a class of drugs called non-structural 5A protein inhibitors, suggesting it's close to ending its partnership with Identix based on its hep C therapies, including the NS5A drug samatasvir, says Wells' Brian Abrahams.

"Hep C battle lines (are) being drawn,” says Abrahams. Idenix’s drug “will need a new partner.”

From other sites
Comments (4)
  • WalkTheTalk
    , contributor
    Comments (470) | Send Message
    "Hep C battle lines (are) being drawn,” says Abrahams.


    A battle between a cat and a lion has begun. "Mew...."
    8 Oct 2013, 05:52 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (884) | Send Message
    should have sold when I was up....
    then again... Idenix will find a new partner easily. The science is there.
    8 Oct 2013, 05:58 PM Reply Like
  • oretiredone
    , contributor
    Comment (1) | Send Message
    I'm just wondering why all these drug companies are futzing around with a much needed treatment for Hep C patients who have failed previous therapies. I they'd work together for the benefit of the patients and not just go for profits maybe a lot of people would be cured of this pernicious disease.
    9 Oct 2013, 09:41 AM Reply Like
  • Nancy Webb
    , contributor
    Comment (1) | Send Message
    Please someone or company find a cure. I have this disease and have tried the other possible cure that almost killed me. Help please!
    9 Oct 2013, 11:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs